The lung is the most common site of

The lung is the most common site of infection in donors. When lung transplantation is under consideration, gram stain and culture of respiratory secretions should be performed. Utilization of lungs with gram-negative bacteria or fungal infections is controversial (RL2-3); some experts favour discarding these organs, while others advocate their use with aggressive antibiotic therapy. Supporting the latter argument, a recent retrospective study demonstrated a high rate of transmission of respiratory tract pathogens to lung recipients (>40%) but overall patient survival was not different to that of recipients of uninfected lungs [12]. Lung recipients should receive treatment according to susceptibility patterns of recovered microorganisms. Additionally, potential donors with upper or lower respiratory tract infection symptoms should be microbiologically tested to rule out influenza infection during the annual influenza epidemic. Donors with confirmed or suspected influenza infection, having received antiviral treatment or not, can be considered for SOT provided that the recipient is prophylactically treated with neuraminidase inhibitors. These donors should be ruled out in the case of lung or intestine transplantation [13].

結果 (繁體中文) 2:

肺是捐贈者最常見的感染部位。在考慮肺移植時，應進行克染色和呼吸分泌物培養。利用肺與克陰性細菌或真菌感染是有爭議的（RL2-3）;一些專家贊成丟棄這些器官，而另一些專家則主張使用積極的抗生素療法。支援後一種觀點，最近的回顧性研究表明，呼吸道病原體向肺部接受者傳播的比率很高（+40%）但總體患者存活率與未感染肺的接受者沒有區別[12]。肺受體應根據恢復微生物的易感性模式接受治療。此外，對有上呼吸道或下呼吸道感染症狀的潛在捐贈者，應進行微生物測試，以排除在年度流感流行期間出現流感感染的可能性。有確診或疑似流感感染的捐贈者，是否接受過抗病毒治療，只要接受者使用神經氨酸酶抑制劑進行預防性治療，可考慮使用SOT。在肺或腸移植的情況下，應排除這些捐贈者[13]。

結果 (繁體中文) 3:

肺是捐獻者最常見的感染部位。在考慮肺移植時，應進行革蘭氏染色和呼吸道分泌物培養。利用帶有革蘭氏陰性細菌或真菌感染的肺部是有爭議的（RL2-3）；一些專家贊成丟棄這些器官，而另一些專家則主張使用積極的抗生素治療。支持後一種觀點的是，最近的一項回顧性研究表明，呼吸道病原體在肺部受者中的傳播率很高（>40%），但總體患者存活率與未受感染肺部受者並無差异[12]。肺部受者應根據復蘇微生物的敏感性模式進行治療。此外，有上呼吸道或下呼吸道感染症狀的潜在捐獻者應接受微生物測試，以排除每年流感流行期間的流感感染。已確診或疑似流感感染的捐贈者，不論是否接受過抗病毒治療，只要接受過神經氨酸酶抑制劑的預防性治療，均可考慮接受SOT。在肺或腸移植的情况下，應該排除這些捐贈者。